Dedicated to Discovering Breakthroughs for Complicated Diseases

Clinical Trials

Clinical trials are vital to driving innovation and advancing science that improves patient lives.
Learn more about SalubrisBio’s clinical trials and how to participate.

Heart Failure

Multiple Phase 1 clinical trials evaluating JK07, an NRG1-HER3 antibody fusion protein, in heart failure patients with reduced ejection fraction (HFrEF) have been completed and pre-clinical studies have demonstrated its potential in heart failure with preserved ejection fraction (HFpEF). Based on positive initial findings from the Phase 1 trials, SalubrisBio has initiated a Phase 2 clinical trial to further evaluate JK07 in HFrEF and HFpEF and is actively recruiting patients.

Solid Tumor Cancers

The first-in-human trial of JK08, an immunocytokine fusion protein comprised of IL15 and a CTLA-4 targeted antibody, in adults with solid tumors is underway and currently enrolling patients for the Phase 1b/2 portion of the program.


A Phase 2 study of JK07 in amyotrophic lateral sclerosis or ALS, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, is expected to initiate in 2024.

Check back soon for more details.